Shukra Pharmaceuticals Ltd
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]
- Market Cap ₹ 491 Cr.
- Current Price ₹ 112
- High / Low ₹ 130 / 30.3
- Stock P/E 34.0
- Book Value ₹ 12.4
- Dividend Yield 0.90 %
- ROCE 44.2 %
- ROE 44.7 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 109% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 30.3%
Cons
- Stock is trading at 8.62 times its book value
- Tax rate seems low
- Working capital days have increased from 90.0 days to 160 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5 | 4 | 3 | 5 | 5 | 5 | 6 | 12 | 11 | 20 | 59 | 75 | 39 | |
5 | 5 | 3 | 4 | 4 | 4 | 4 | 10 | 10 | 18 | 53 | 55 | 23 | |
Operating Profit | 0 | -0 | -0 | 1 | 1 | 2 | 2 | 2 | 1 | 3 | 5 | 19 | 15 |
OPM % | 9% | -2% | -10% | 24% | 28% | 30% | 29% | 13% | 13% | 14% | 9% | 26% | 40% |
-3 | 0 | 1 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 4 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
Profit before tax | -3 | -1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 4 | 20 | 16 |
Tax % | 0% | 9% | 52% | 66% | 52% | 45% | 37% | 82% | -90% | 26% | 1% | 7% | |
-3 | -1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 4 | 19 | 14 | |
EPS in Rs | -0.09 | -0.17 | 0.03 | 0.03 | 0.11 | 0.12 | 0.10 | 0.01 | 0.04 | 0.17 | 1.00 | 4.23 | 3.32 |
Dividend Payout % | 0% | 0% | 0% | 0% | 16% | 15% | 17% | 0% | 0% | 10% | 4% | 6% |
Compounded Sales Growth | |
---|---|
10 Years: | 33% |
5 Years: | 67% |
3 Years: | 88% |
TTM: | -59% |
Compounded Profit Growth | |
---|---|
10 Years: | 39% |
5 Years: | 109% |
3 Years: | 410% |
TTM: | 58% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 112% |
3 Years: | 193% |
1 Year: | 219% |
Return on Equity | |
---|---|
10 Years: | 14% |
5 Years: | 22% |
3 Years: | 30% |
Last Year: | 45% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 11 | 44 |
Reserves | -11 | 12 | 12 | 13 | 13 | 13 | 14 | 14 | 14 | 15 | 21 | 47 | 10 |
10 | 0 | 1 | 0 | 0 | 4 | 6 | 8 | 10 | 3 | 5 | 3 | 3 | |
4 | 4 | 3 | 3 | 4 | 6 | 7 | 10 | 10 | 15 | 45 | 17 | 24 | |
Total Liabilities | 14 | 18 | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 78 | 81 |
10 | 10 | 10 | 10 | 10 | 14 | 16 | 17 | 18 | 18 | 20 | 20 | 20 | |
CWIP | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
3 | 7 | 7 | 6 | 7 | 8 | 11 | 14 | 16 | 16 | 53 | 56 | 59 | |
Total Assets | 14 | 18 | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 78 | 81 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-12 | -3 | -2 | 3 | -0 | 1 | 0 | 1 | 1 | 8 | 3 | -5 | |
2 | -10 | 1 | -0 | -1 | -5 | -2 | -3 | -2 | -2 | -4 | -1 | |
5 | -18 | 1 | -1 | 0 | 3 | 2 | 2 | 2 | -7 | 5 | 12 | |
Net Cash Flow | -5 | -31 | 0 | 1 | -1 | -0 | 0 | -0 | 0 | -0 | 4 | 6 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 92 | 45 | 73 | 71 | 175 | 200 | 345 | 245 | 318 | 132 | 187 | 120 |
Inventory Days | 145 | 134 | 554 | 92 | 112 | 53 | 100 | 169 | 221 | 139 | 25 | 19 |
Days Payable | 173 | 209 | 291 | 108 | 400 | 734 | 1,161 | 786 | 702 | 303 | 271 | 59 |
Cash Conversion Cycle | 64 | -30 | 335 | 54 | -112 | -480 | -717 | -372 | -163 | -32 | -58 | 80 |
Working Capital Days | 111 | 368 | 758 | 258 | 344 | 379 | 440 | 226 | 278 | 61 | 49 | 160 |
ROCE % | -2% | -6% | -1% | 6% | 7% | 6% | 4% | 0% | 1% | 6% | 19% | 44% |
Documents
Announcements
-
Announcement Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulation 2015 ('SEBI LODR") For Intimation For Receipt Of In- Principal Approval From Stock Exchange Under Regulation 28(1) Of SEBI LODR
29 Nov - In-principal approval for rights issue of Rs.36 Cr.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Nov - Submission of unaudited financial results for Q2 2024.
- Un-Audited Financial Results Of The Company For The Second Quarter And Half Year Ended On 30Th September, 2024. 14 Nov
-
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. On 14Th November, 2024 And Submission Of Un-Audited Financial Results Of The Company For The Second Quarter And Half Year Ended On 30Th September, 2024.
14 Nov - Outcome of Board Meeting and financial results for Q2 2024.
-
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 And 33 Of SEBI (LODR) Regulations, 2015
7 Nov - Board meeting to approve financial results on Nov 14, 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
SPL is a is WHO-GMP certified integrated manufacturer of formulations like tablet, capsules and small volume parenteral. It has assisted in the development and manufacture
of a variety of drugs and dosage forms and potency variations for many pharmaceutical companies